Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPD | P32754 | 3/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 14/20 | 0.41 |
| ▸ | PRKDC | P78527 | 11/20 | 0.41 |
| ▸ | MTOR | P42345 | 4/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.38 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
| ▸ | CSF1R | P07333 | 1/20 | 0.37 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.37 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.37 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.37 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5836683 | 0.78 | KDM4E (0.50) | HPDPIK3CAPRKDCMTORHSD11B1 | |
| SCHEMBL5836096 | 0.74 | HPD (0.52) | HPDPIK3CAPRKDCMTORHSD11B1 | |
| SCHEMBL5838061 | 0.74 | DRD2 (0.49) | HPDPIK3CAPRKDCMTORHSD11B1 | |
| SCHEMBL5838051 | 0.71 | DRD2 (0.52) | HPDPIK3CAPRKDCMTORHSD11B1 | |
| SCHEMBL22493213 | 0.70 | MAOB (0.46) | — | |
| SCHEMBL5836181 | 0.69 | HPD (0.53) | HPDPIK3CAPRKDCMTORHSD11B1 | |
| SCHEMBL5836224 | 0.69 | DRD2 (0.46) | HPDPIK3CAPRKDCMTORDDB1 | |
| SCHEMBL6208794 | 0.66 | HPD (0.56) | HPDPIK3CAPRKDCMTORHSD11B1 | |
| SCHEMBL1515840 | 0.66 | LMNA (0.54) | — | |
| SCHEMBL5836712 | 0.66 | HPD (0.50) | HPDPIK3CAPRKDCMTORHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7056918-B2 | Benzimidazole anti-inflammatory compounds | PFIZER, INC. (US) | 2006-06-06 | — | — | US | disclosed |
| EP-1370557-B1 | BENZIMIDAZOLE ANTI-INFLAMMATORY COMPOUNDS | PFIZER PROD INC (US) | 2005-11-16 | — | — | EP | disclosed |
| EP-1370557-A1 | BENZIMIDAZOLE ANTI-INFLAMMATORY COMPOUNDS | Pfizer Products Inc. (US) | 2003-12-17 | — | — | EP | disclosed |
| US-20030092749-A1 | Novel benzimidazole anti-inflammatory compounds | PFIZER INC. | 2003-05-15 | — | — | US | disclosed |
| WO-2002072576-A1 | BENZIMIDAZOLE ANTI-INFLAMMATORY COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2002-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092749-A1 | Novel benzimidazole anti-inflammatory compounds | MAPK1, JAK1, CNKSR1 | HPD 4598/4885PIK3CA 1672/4885PRKDC 1727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.